|Articles|June 8, 2022
Tissue IHC: Translating Technology into Patient Testing After Biomarker Target is ID
Author(s)Frontage Laboratories, Inc.
In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical, but how do you translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified?
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
2
FDA Issues Draft Guidance to Advance Bayesian Methods in Clinical Trials
3
Extending Trial Registries for an AI-Driven Era of Patient Discovery
4
ACT Brief: Moving Beyond AI Pilots, FDA Advances Bayesian Trials, and Sites Strained by Trial Design
5